Ellis R, et al. - Whether combined epidermal AMBRA1/Loricrin (AMLo) expression can be a prognostic biomarker for AJCC stage I cutaneous melanoma was determined by researchers. A retrospective discovery cohort of 76 AJCC I melanomas was evaluated for peri-tumoral AMBRA1 expression. In two independent powered, retrospective validation and qualification cohorts consisting of 379 AJCC I melanomas, multivariate analysis of AMLo expression was then correlated with clinical results up to 12 years. According to findings, high-risk tumor subsets are identified by loss of AMLo expression in the epidermis overlying primary AJCC stage I melanomas, regardless of Breslow depth. This brings about a major shift in future prognostic evaluation and stratification of primary melanomas.